Press releases Image Corporate / 22.11.2021 IBA – TRANSPARENCY NOTIFICATION - Norges Bank Read more IBA – TRANSPARENCY NOTIFICATION - Norges Bank
Press releases Image EN FR Proton Therapy / 19.11.2021 IBA and the Oncology Reference Center of Aviano, Italy, sign contract to install a Proteus®ONE Proton Therapy system Read more IBA and the Oncology Reference Center of Aviano, Italy, sign contract to install a Proteus®ONE Proton Therapy system
Press releases Image EN FR Corporate / 18.11.2021 IBA BUSINESS UPDATE – THIRD QUARTER 2021 Read more IBA BUSINESS UPDATE – THIRD QUARTER 2021
Press releases Image EN RadioPharma Solutions / 18.11.2021 IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Actinium-225 (Ac-225) Read more IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Actinium-225 (Ac-225)
Press releases Image EN FR Industrial Solutions / 28.10.2021 IBA and TRAD Tests & Radiations announce collaboration to develop next generation radiation processing application Read more IBA and TRAD Tests & Radiations announce collaboration to develop next generation radiation processing application
Press releases Image EN Proton Therapy / 26.10.2021 IBA and RaySearch expand their partnership in proton therapy Read more IBA and RaySearch expand their partnership in proton therapy
Press releases Image EN Proton Therapy / 25.10.2021 IBA and the University of Pennsylvania partner to advance research of ConformalFLASH® therapy Read more IBA and the University of Pennsylvania partner to advance research of ConformalFLASH® therapy
Press releases Image EN FR Proton Therapy / 24.10.2021 Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida Read more Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida
Press releases Image FR EN Proton Therapy / 20.10.2021 IBA launches Campus: the world’s first online proton therapy platform Read more IBA launches Campus: the world’s first online proton therapy platform
Press releases Image EN FR Corporate / 08.10.2021 IBA – ACQUISITION OF OWN SHARES COMPLETION OF THE SHARE BUYBACK PROGRAM Read more IBA – ACQUISITION OF OWN SHARES COMPLETION OF THE SHARE BUYBACK PROGRAM
Press releases Image EN FR Corporate / 01.10.2021 October 1st, 2021 - IBA Acquisition of own shares Read more October 1st, 2021 - IBA Acquisition of own shares
Press releases Image EN RadioPharma Solutions / 28.09.2021 ICNAS/University of Coimbra granted with first EU marketing authorization for the distribution of cyclotron produced Gallium-68 Read more ICNAS/University of Coimbra granted with first EU marketing authorization for the distribution of cyclotron produced Gallium-68
Press releases Image EN FR Corporate / 24.09.2021 September 24th, 2021 - IBA Acquisition of own shares Read more September 24th, 2021 - IBA Acquisition of own shares
Press releases Image EN FR Corporate / 17.09.2021 September 17th, 2021 - IBA Acquisition of own shares Read more September 17th, 2021 - IBA Acquisition of own shares
Press releases Image EN FR NL Corporate / 15.09.2021 IBA and SCK CEN join forces to enable production of Actinium-225 Read more IBA and SCK CEN join forces to enable production of Actinium-225
Reports Image EN FR Corporate / 13.09.2021 IFRS Interim Condensed Consolidated Financial Statements June 30, 2021 Read more IFRS Interim Condensed Consolidated Financial Statements June 30, 2021
Press releases Image EN FR Corporate / 10.09.2021 September 10, 2021 - IBA Acquisition of own shares Read more September 10, 2021 - IBA Acquisition of own shares
Press releases Image Corporate / 03.09.2021 IBA – ACQUISITION OF OWN SHARES Read more IBA – ACQUISITION OF OWN SHARES
Press releases Image EN FR Corporate / 01.09.2021 IBA - TRANSPARENCY NOTIFICATION Read more IBA - TRANSPARENCY NOTIFICATION
Press releases Image EN FR Corporate / 31.08.2021 August 31st, 2021 Executives acquire a 1.16% long term interest in IBA Read more August 31st, 2021 Executives acquire a 1.16% long term interest in IBA
